REACT-AF is a study for people aged 22-85 with a type of irregular heartbeat called Atrial Fibrillation (AF). This study compares two approaches using blood thinners called Direct Oral Anticoagulants (DOACs). One approach is to take DOACs continuously, and the other is to take them only for 30 days when the AF is detected by a Smart Watch. If you have a moderate risk of stroke, this study might be for you. The stroke risk is calculated using a score called CHA2DS2-VASc. Participants need to wear a smart watch for at least 14 hours a day and must have a compatible smartphone. The study will last up to 60 months, or 5 years.
- Participants must be willing to wear a smart watch and use a smartphone.
- The study might last up to 5 years, with regular check-ins.
- Participants should not be on other strong blood thinners like warfarin.